Examining funding in light of new evidence on HIV prevention, treatment strategies

NewsGuard 100/100 Score

In this Huffington Post opinion piece, Nancy Birdsall, president of the Center for Global Development, reports on a World Bank- and USAID-sponsored debate she moderated last week as part of a series on HIV/AIDS issues, the topic of which was "Countries should spend a majority of what is likely to be a flat or even declining HIV prevention budget on 'treatment as prevention.'" She notes several of her reactions to the debate and asks with regard to global health spending, "What about the pie? Even if it grows, there will be tradeoffs."   

She concludes, "The debate about allocation of this (apparently fixed) HIV/AIDS pie between prevention and treatment ... is newly raging because of new evidence from a randomized controlled trial: much earlier use of anti-AIDS drugs ("treatment") is in a biological sense hugely effective in preventing transmission of HIV-infected people to their partners. ... Could this new exciting evidence mean the AIDS pie, which has stopped growing in the last couple of years, will now grow again?" (11/16).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
U-M research offers a new path forward in the development of anti-HIV drugs